On July 5, AstraZeneca announced that it intends to acquire biotech company TeneoTwo and will receive a bispecific molecular therapy in Phase 1 clinical trials. AstraZeneca will pay an up-front amount of $100 million, taking into account milestone payments, up to a total of about $1.27 billion.
The transaction is expected to close in the third quarter of 2022, and through the acquisition of TeneoTwo, AstraZeneca will gain access to its Phase I CD19/CD3 T-cell engager TNB-486, which is currently being tested for relapsed and refractory B-cell non-cholesterol Chikin lymphoma was assessed. TNB-486 belongs to a class of therapeutic antibodies known as T-cell engagers, which are bispecific molecules designed to redirect the immune system’s T cells to recognize and kill cancer cells. TNB-486 activates and recruits T cells to CD19-expressing tumors by binding to CD19, an antigen expressed on B cells, and the CD3 receptor on T cells, never eliciting an immune response for therapy cancer.
TNB-486 is currently being evaluated in relapsed and refractory B-cell non-Hodgkin lymphoma. With the acquisition of this innovative therapy, the company expects to further accelerate the development of this innovative therapy in B-cell malignant hematological cancers, including large B-cell lymphoma and follicular lymphoma.
AstraZeneca’s vision is to redefine cancer care and one day eliminate cancer as a cause of death. AstraZeneca is pushing the boundaries of science to redefine the standard of care in hematology. Anas Younes, Senior Vice President, Hematology R&D, AstraZeneca, said: “By redirecting the body’s natural immune response to target B-cell malignancies, TNB-486 alone or in combination with CD20-targeted therapy may deepen clinical responses and improve clinical outcomes. Patient outcomes. We believe that this innovative molecule designed to optimize the therapeutic window for T cell activation will allow us to explore new combinations that will hopefully provide a new standard of care for patients.”